
C Warren Olanow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9588405/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Movement Disorder Societyâ€sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSâ€UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 2008, 23, 2129-2170.	3.9	4,796
2	Levodopa and the Progression of Parkinson's Disease. New England Journal of Medicine, 2004, 351, 2498-2508.	27.0	1,649
3	Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine, 2008, 14, 504-506.	30.7	1,472
4	A doubleâ€blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology, 2003, 54, 403-414.	5.3	1,450
5	Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain, 2013, 136, 2419-2431.	7.6	965
6	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. New England Journal of Medicine, 2009, 361, 1268-1278.	27.0	830
7	Pathophysiology of the basal ganglia in Parkinson's disease. Trends in Neurosciences, 2000, 23, S8-S19.	8.6	702
8	The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology, 2009, 72, S1-136.	1.1	685
9	Understanding cell death in parkinson's disease. Annals of Neurology, 1998, 44, S72-84.	5.3	605
10	Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology, The, 2010, 9, 1164-1172.	10.2	589
11	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology, The, 2014, 13, 141-149.	10.2	547
12	Failure of the ubiquitin–proteasome system in Parkinson's disease. Nature Reviews Neuroscience, 2001, 2, 589-594.	10.2	490
13	Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurology, The, 2006, 5, 677-687.	10.2	461
14	Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurology, The, 2015, 14, 855-866.	10.2	393
15	Factors predictive of the development of Levodopaâ€induced dyskinesia and wearingâ€off in Parkinson's disease. Movement Disorders, 2013, 28, 1064-1071.	3.9	374
16	Subthalamic nucleusâ€mediated excitotoxicity in parkinson's disease: A target for neuroprotection. Annals of Neurology, 1998, 44, S175-88.	5.3	344
17	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet, The, 2014, 384, 545-555.	13.7	336
18	Levodopa in the treatment of Parkinson's disease: Current controversies. Movement Disorders, 2004, 19, 997-1005.	3.9	331

#	Article	IF	CITATIONS
19	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDEâ€PD study. Annals of Neurology, 2010, 68, 18-27.	5.3	330
20	Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‣ike Disorder?. Movement Disorders, 2013, 28, 31-40.	3.9	320
21	Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurology, The, 2004, 3, 496-503.	10.2	278
22	Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Movement Disorders, 1998, 13, 383-393.	3.9	271
23	Is Parkinson's disease a prion disorder?. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12571-12572.	7.1	242
24	Gene delivery of neurturin to putamen and substantia nigra in <scp>P</scp> arkinson disease: A doubleâ€blind, randomized, controlled trial. Annals of Neurology, 2015, 78, 248-257.	5.3	224
25	Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease. Archives of Neurology, 2005, 62, 905-10.	4.5	206
26	The pathogenesis of cell death in Parkinson's disease – 2007. Movement Disorders, 2007, 22, S335-S342.	3.9	191
27	Ubiquitin–proteasome system and Parkinson's disease. Movement Disorders, 2006, 21, 1806-1823.	3.9	175
28	TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology, The, 2006, 5, 1013-1020.	10.2	167
29	The Scientific Basis for the Current Treatment of Parkinson's Disease. Annual Review of Medicine, 2004, 55, 41-60.	12.2	165
30	Waking up to sleep episodes in Parkinson's Disease. Movement Disorders, 2000, 15, 212-215.	3.9	163
31	A randomized, doubleâ€blind, placebo ontrolled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. Movement Disorders, 2008, 23, 2194-2201.	3.9	162
32	Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study). Clinical Neuropharmacology, 2004, 27, 58-62.	0.7	161
33	Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain, 2002, 125, 2058-2066.	7.6	145
34	Why have we failed to achieve neuroprotection in Parkinson's disease?. Annals of Neurology, 2008, 64, S101-S110.	5.3	125
35	Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications. European Polymer Journal, 2017, 88, 524-552.	5.4	124
36	Therapeutic prospects for Parkinson disease. Annals of Neurology, 2013, 74, 337-347.	5.3	122

#	Article	IF	CITATIONS
37	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurology, The, 2014, 13, 767-776.	10.2	120
38	Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nature Clinical Practice Neurology, 2006, 2, 382-392.	2.5	117
39	Movement disorder society criteria for clinically established early Parkinson's disease. Movement Disorders, 2018, 33, 1643-1646.	3.9	114
40	Dopamine agonists and neuroprotection in parkinson's disease. Annals of Neurology, 1998, 44, S167-74.	5.3	108
41	Fetal Grafting for Parkinson's Disease: Expression of Immune Markers in Two Patients with Functional Fetal Nigral Implants. Cell Transplantation, 1997, 6, 213-219.	2.5	107
42	<scp>l</scp> â€Deprenyl Protects Mesencephalic Dopamine Neurons from Glutamate Receptorâ€Mediated Toxicity In Vitro. Journal of Neurochemistry, 1997, 68, 33-39.	3.9	89
43	Levodopa: A new look at an old friend. Movement Disorders, 2018, 33, 859-866.	3.9	89
44	Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind videoâ€based analysis. Movement Disorders, 2009, 24, 336-343.	3.9	84
45	Tolcapone. Clinical Neuropharmacology, 2007, 30, 287-294.	0.7	83
46	Levodopa: Effect on cell death and the natural history of Parkinson's disease. Movement Disorders, 2015, 30, 37-44.	3.9	83
47	Dopaminergic transplantation for parkinson's disease: Current status and future prospects. Annals of Neurology, 2009, 66, 591-596.	5.3	80
48	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurology, The, 2020, 19, 135-144.	10.2	80
49	Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson's disease. Brain, 2019, 142, 1690-1700.	7.6	75
50	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a <scp>P</scp> arkinson disease patient. Annals of Neurology, 2017, 81, 46-57.	5.3	72
51	COMT inhibitors in Parkinson's disease. Neurology, 2004, 62, S72-81.	1.1	70
52	The significance of defining preclinical or prodromal Parkinson's disease. Movement Disorders, 2012, 27, 666-669.	3.9	69
53	Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. Movement Disorders, 2016, 31, 1366-1372.	3.9	67
54	Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology, 2006, 66, S69-79.	1.1	67

#	Article	IF	CITATIONS
55	The causes of parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Annals of Neurology, 1998, 44, S189-96.	5.3	65
56	<scp>l</scp> â€(â^')â€Desmethylselegiline, a Metabolite of Selegiline [<scp>l</scp> â€(â^')â€Deprenyl], Protects Mesencephalic Dopamine Neurons from Excitotoxicity In Vitro. Journal of Neurochemistry, 1997, 68, 434-436.	3.9	61
57	Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Movement Disorders, 2000, 15, 485-489.	3.9	60
58	Can we achieve neuroprotection with currently available anti-parkinsonian interventions?. Neurology, 2009, 72, S59-64.	1.1	57
59	Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain, 2020, 143, 960-975.	7.6	56
60	Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy. Movement Disorders, 2005, 20, S3-S10.	3.9	55
61	Trophic factors for Parkinson's disease: To live or let die. Movement Disorders, 2015, 30, 1715-1724.	3.9	55
62	Levodopa/dopamine replacement strategies in Parkinson's disease-Future directions. Movement Disorders, 2008, 23, S613-S622.	3.9	52
63	Parkinsonism associated with Sj�gren's syndrome: Three cases and a review of the literature. Movement Disorders, 1999, 14, 262-268.	3.9	51
64	Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities. Movement Disorders, 2020, 35, 1731-1744.	3.9	47
65	Glial Cells Mediate Toxicity in Glutathione-Depleted Mesencephalic Cultures. Journal of Neurochemistry, 2002, 73, 112-119.	3.9	46
66	Longâ€ŧerm effects of rasagiline and the natural history of treated Parkinson's disease. Movement Disorders, 2016, 31, 1489-1496.	3.9	45
67	Parkinson's disease, proteins, and prions: Milestones. Movement Disorders, 2011, 26, 1056-1071.	3.9	36
68	Do prions cause Parkinson disease?: The evidence accumulates. Annals of Neurology, 2014, 75, 331-333.	5.3	34
69	Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. Journal of Parkinson's Disease, 2021, 11, 177-186.	2.8	33
70	Peripheral alphaâ€synuclein and Parkinson's disease. Movement Disorders, 2014, 29, 963-966.	3.9	32
71	The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology, 2002, 58, S33-41.	1.1	32
72	Defining diseaseâ€modifying therapies for PD—A road map for moving forward. Movement Disorders, 2010, 25, 1774-1779.	3.9	31

#	Article	IF	CITATIONS
73	The Vatican Meeting on Neuroprotection for Parkinson's Disease. Movement Disorders, 2013, 28, 1-2.	3.9	26
74	Targeting α-Synuclein as a therapy for Parkinson's disease: The battle begins. Movement Disorders, 2017, 32, 203-207.	3.9	26
75	<scp>Onceâ€Weekly</scp> Subcutaneous Delivery of <scp>Polymerâ€Linked</scp> Rotigotine (<scp>SER</scp> â€214) Provides Continuous Plasma Levels in Parkinson's Disease Patients. Movement Disorders, 2020, 35, 1055-1061.	3.9	24
76	The delayed-start study in Parkinson disease. Neurology, 2010, 74, 1149-1150.	1.1	21
77	Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity. Movement Disorders, 2022, 37, 6-15.	3.9	21
78	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1 <scp>‥ear</scp> Data from the <scp>Open‣abel BeyoND</scp> Study. Movement Disorders, 2021, 36, 2687-2692.	3.9	20
79	Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. Journal of Huntington's Disease, 2020, 9, 371-380.	1.9	17
80	Present and future directions in the management of motor complications in patients with advanced PD. Neurology, 2003, 61, S24-33.	1.1	17
81	Milestones in movement disorders clinical trials: Advances and landmark studies. Movement Disorders, 2011, 26, 1003-1014.	3.9	16
82	<scp>Onâ€Demand</scp> Therapy for <scp>OFF</scp> Episodes in Parkinson's Disease. Movement Disorders, 2021, 36, 2244-2253.	3.9	16
83	Dietary vitamin E and Parkinson's disease: something to chew on. Lancet Neurology, The, 2003, 2, 74.	10.2	15
84	Levodopa therapy for Parkinson's disease: Challenges and future prospects. Movement Disorders, 2008, 23, S495-S496.	3.9	14
85	A New Approach to the Development of Diseaseâ€Modifying Therapies for PD ; Fighting Another Pandemic. Movement Disorders, 2021, 36, 59-63.	3.9	13
86	Gene therapy for Parkinson disease—a hope, or a dream?. Nature Reviews Neurology, 2014, 10, 186-187.	10.1	12
87	Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study. Movement Disorders, 2019, 34, 425-429.	3.9	11
88	Advances in clinical trials for movement disorders. Movement Disorders, 2015, 30, 1580-1587.	3.9	8
89	Fetal grafts for Parkinson's disease: Decades in the making. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6332-6334.	7.1	8
90	Dose optimization of apomorphine sublingual film for treating "OFF―episodes in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 93, 27-30.	2.2	8

#	Article	IF	CITATIONS
91	Reply: Levodopa in the treatment of Parkinson's disease: Current controversies. Movement Disorders, 2005, 20, 643-644.	3.9	7
92	Movement disorders: a step in the right direction. Lancet Neurology, The, 2006, 5, 3-5.	10.2	5
93	Reply to Montgomery. Annals of Neurology, 2009, 65, 618-619.	5.3	5
94	The baton is passed. Movement Disorders, 2010, 25, 1-1.	3.9	5
95	Initiating levodopa therapy for Parkinson's disease. Movement Disorders, 2014, 29, 430-430.	3.9	5
96	Profile of Mahlon DeLong and Alim Benabid, 2014 Lasker-DeBakey Medical Research Awardees. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17693-17695.	7.1	2
97	Translating scientific advances into disease-modifying therapies for Parkinson's Disease. Experimental Neurology, 2017, 298, 135-136.	4.1	1
98	Adverse event reporting in clinical trials in Parkinson's Disease: Time for change. Movement Disorders, 2018, 33, 1685-1687.	3.9	1
99	<i>Movement Disorders</i> Journal: Yesterday, Today, Tomorrow, and Always. Movement Disorders, 2019, 34, 1814-1816.	3.9	1
100	The Etiopathogenesis of Parkinson's Disease: Basic Mechanisms of Neurodegeneration. , 2008, , 1-23.		0
101	The Movement Disorders journal-Then and now. Movement Disorders, 2011, 26, 935-936.	3.9	0
102	New Sections for <i>Movement</i> Disorders. Movement Disorders, 2011, 26, 2179-2179.	3.9	0
103	The state of the journal—2013. Movement Disorders, 2013, 28, 259-260.	3.9	0
104	Eldad Melamed 1942-2015: Ave atque-A memorial. Movement Disorders, 2016, 31, 39-40.	3.9	0
105	A Model-Based Approach for Assessing Parkinsonian Gait and Effects of Levodopa and Deep Brain Stimulation. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006	0.5	0